Acrivon Therapeutics, Inc. ( NASDAQ:ACRV – Get Free Report ) has received an average rating of 'Buy' from the nine brokerages that are covering the firm, Marketbeat.com reports. Nine analysts have rated the stock with a buy rating. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $22.86. ACRV has been the topic of a number of analyst reports. Oppenheimer assumed coverage on shares of Acrivon Therapeutics in a research report on Thursday, June 1st.

https://www.dailypolitical.com/2023/09/01/acrivon-therapeutics-inc-nasdaqacrv-receives-22-86-consensus-target-price-from-analysts.html

#dailypolitical